Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2014, Article ID 267535, 4 pages
http://dx.doi.org/10.1155/2014/267535
Case Report

Melanoma Arising after Imiquimod Use

1University of Auckland, Auckland 1010, New Zealand
2University of Queensland, Brisbane, QLD 4072, Australia
3Skin Surgery Clinic, Auckland 0600, New Zealand

Received 31 August 2014; Accepted 16 October 2014; Published 9 November 2014

Academic Editor: Jeffrey M. Weinberg

Copyright © 2014 Sharad P. Paul. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. Harrison, L. Jenski, T. Voychehovski, and D. I. Bernstein, “Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection,” Antiviral Research, vol. 10, no. 4-5, pp. 209–224, 1988. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Gerster, K. J. Lindstrom, R. L. Miller et al., “Synthesis and structure—activity-relationships of 1H-imidazo[4,5-c] quinolines that induce interferon production,” Journal of Medicinal Chemistry, vol. 48, no. 10, pp. 3481–3491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Salasche, N. Levine, and L. Morrison, “Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial,” Journal of the American Academy of Dermatology, vol. 47, no. 4, pp. 571–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. K. R. Beutner, J. K. Geisse, D. Helman, T. L. Fox, A. Ginkel, and M. L. Owens, “Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream,” Journal of the American Academy of Dermatology, vol. 41, no. 6, pp. 1002–1007, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. E. C. Smyth, M. Flavin, M. P. Pulitzer et al., “Treatment of locally recurrent mucosal melanoma with topical imiquimod,” Journal of Clinical Oncology, vol. 29, no. 33, pp. e809–e811, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Gagnon, “Imiquimod advantage,” Dermatology Times, vol. 32, no. 9, pp. 86–89, 2011. View at Google Scholar
  7. M. A. Stanley, “Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential,” Clinical and Experimental Dermatology, vol. 27, no. 7, pp. 571–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. J. Gibson, J. M. Lindh, T. R. Riter et al., “Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod,” Cellular Immunology, vol. 218, no. 1-2, pp. 74–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kaisho and S. Akira, “Toll-like receptor function and signaling,” Journal of Allergy and Clinical Immunology, vol. 117, no. 5, pp. 979–987, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. A. Tomai, L. M. Imbertson, T. L. Stanczak, L. T. Tygrett, and T. J. Waldschmidt, “The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes,” Cellular Immunology, vol. 203, no. 1, pp. 55–65, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Y. Goh, “Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream,” Australasian Journal of Dermatology, vol. 47, no. 3, pp. 186–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Campalani and C. A. Holden, “Keratoacanthoma associated with the use of topical imiquimod,” Clinical and Experimental Dermatology, vol. 38, no. 5, pp. 555–556, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Chapman, S. K. Spencer, and J. B. Brennick, “Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream,” Archives of Dermatology, vol. 139, no. 7, pp. 943–944, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Kamin, T. K. Eigentler, P. Radny, J. Bauer, B. Weide, and C. Garbe, “Imiquimod in the treatment of extensive recurrent lentigo maligna,” Journal of the American Academy of Dermatology, vol. 52, no. 2, supplement 1, pp. S51–S52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Aspord, L. Tramcourt, C. Leloup et al., “Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization,” Journal of Investigative Dermatology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. B. Bong, B. Bonnekoh, I. Franke, M. P. Schön, J. Ulrich, and H. Gollnick, “Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma,” Dermatology (Basel, Switzerland), vol. 205, no. 2, pp. 135–138, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. K. J. Ashton, S. R. Weinstein, D. J. Maguire, and L. R. Griffiths, “Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization,” Archives of Dermatology, vol. 139, no. 7, pp. 876–882, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Brash, A. Ziegler, A. S. Jonason, J. A. Simon, S. Kunala, and D. J. Leffell, “Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion,” Journal of Investigative Dermatology Symposium Proceedings, vol. 1, no. 2, pp. 136–142, 1996. View at Google Scholar · View at Scopus
  19. S. T. McGillis and H. Fein, “Topical treatment strategies for non-melanoma skin cancer and precursor lesions,” Seminars in Cutaneous Medicine and Surgery, vol. 23, no. 3, pp. 174–183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Akkilic-Materna, C. Massone, and P. Komericki, “Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer,” Acta Dermato-Venereologica, vol. 91, no. 4, pp. 432–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Skaria, “Facial basal cell carcinomas recurring after imiquimod therapy,” Dermatology, vol. 226, no. 1, pp. 13–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Fernández-Vozmediano and J. Armario-Hita, “Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream,” Journal of the American Academy of Dermatology, vol. 52, no. 4, pp. 716–717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Leroy, F. Wolf, J. Descotes, and T. Vial, “Imiquimod and pulmonary embolism: a case report,” Fundamental and Clinical Pharmacology, vol. 26, supplement 1, p. 98, 2012, abstr. P375. View at Google Scholar
  24. A. Lapresta, D. García-Almagro, and A. G. Sejas, “Amelanotic lentigo maligna managed with topical imiquimod,” The Journal of Dermatology, vol. 39, no. 5, pp. 503–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J. O'Neill, D. Ayers, and J. Kenealy, “Periocular lentigo maligna treated with imiquimod,” Journal of Dermatological Treatment, vol. 22, no. 2, pp. 109–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Ventura, J. Rocha, J. C. Fernandes, F. Pardal, and C. Brito, “Topical imiquimod treatment of Lentigo Maligna,” Case Reports in Dermatology, vol. 1, pp. 78–81, 2009. View at Publisher · View at Google Scholar
  27. M. A. Cotter, J. K. McKenna, and G. M. Bowen, “Treatment of lentigo maligna with imiquimod before staged excision,” Dermatologic Surgery, vol. 34, no. 2, pp. 147–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Schön, A. B. Bong, C. Drewniok et al., “Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod,” Journal of the National Cancer Institute, vol. 95, no. 15, pp. 1138–1149, 2003. View at Publisher · View at Google Scholar · View at Scopus